Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22311884 | 0.84 | — | — | |
| SCHEMBL12955575 | 0.84 | — | — | |
| SCHEMBL14434380 | 0.84 | — | — | |
| SCHEMBL44881 | 0.84 | — | — | |
| SCHEMBL44882 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL16245107 | 0.81 | MAPK1 (0.52) | MAPK1LMNACYP2C9CHRM3CHRM2 | |
| Charcoal, Activated SCHEMBL11101400 | 0.81 | MAPK1 (0.52) | MAPK1LMNACYP2C9CHRM3CHRM2 | |
| Iodide SCHEMBL5266075 | 0.81 | MAPK1 (0.52) | MAPK1LMNACYP2C9CHRM3CHRM2 | |
| Hydrochloric Acid SCHEMBL16245108 | 0.81 | MAPK1 (0.52) | MAPK1LMNACYP2C9CHRM3CHRM2 | |
| SCHEMBL1848113 | 0.81 | MAPK1 (0.52) | MAPK1LMNACYP2C9CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-8530477-B2 | Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betaHSD1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| EP-2364311-B1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-2364311-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI (FR) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364311-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI (FR) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010049635-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049635-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294809-A1 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 | HSD11B1, HSD17B1, HSD17B11 | MAPK1 1320/4885LMNA 2460/4885CYP2C9 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.